Efficacy, Safety and Protective Effects of Lipid Lowering Drugs in Patients with Diabetes

##plugins.themes.bootstrap3.article.main##

  •   Y. Htira

  •   M. Dridi

  •   Z. Hadj Ali

  •   N. Trabelsi

  •   F. Ben Mami

Abstract

Aim: The aim of the study was to assess the effects of statins and fibrates on the lipid profile of patients with diabetes and to determine their side effects.


Methods: It was a transversal study. We included patients with type 1 or 2 diabetes that are followed in an outpatient department, treated for at least 3 months by statins or fibrates.We performed an interrogatory, a medical examination, dietary survey and biological tests for all patients.


Results:The mean age was 59.5 ± 9.2 years. Women were 65% of patients. The mean duration of treatment with statins and fibrates was 2.2 ± 2.6 years and 4.9 ± 4.2 years, respectively.Under statin therapy, total cholesterol and LDL cholesterol decreased significantly by 1.02±1.25 mmol/l and 0.32±0.47 mmol/l, respectively, triglycerides and HDL cholesterol decreased insignificantly.Fibrates caused a significant decrease in total cholesterol and triglycerides by 1.15± 2.24 mmol/l and 1.73 ±2.96 mmol/l, respectively and a non-significant decrease in LDL cholesterol and a non-significant increase in HDL cholesterol. No case of significant hepatic cytolysis was noted. Muscle pain was reported by 10.4% and 11.6% of patients on statins and fibrate, respectively.Under statins, the incidence of gastrointestinal symptoms increased significantly.


Conclusion: The efficacy of lipid lowering drugs is widely proven. Although side effects are possible, the prescription of lipid lowering drugs should be largely encouraged for better health care of patients with diabetes.


Keywords: Diabetes, Fenofibrate, lipids, statin

References

American diabetes association. Standards of medical care in diabetes. Diabetes care. 2020.

NaciH,Brugts JJ,Fleurence R,Ades A.Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur J PrevCardiol. 2013;20:658-70.

The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet.1994;344(8934):1383-9.

Sacks FM, Pfeffer MA, Lemuel A, Moye PH, Rouleau MD, Rutherford JD. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.

Long term intervention with pravastatin in ischemic disease (LIPID) Study Goup. N. Engl J Med. 1998;339(8):349-57.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet.2002(9326);360:7-22.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med.1995;333(20):1301-7.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentrerandomised controlled trial. Lancet 2003;361:1149-58.

Knopp RH, D’Hemden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care.2006;29(7):1478-85.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentrerandomised placebo-controlled trial. Lancet. 2004;364(9435):685-96.

Deedwania PC,Hunninghake DB,Bays HE,Jones PH,CainVA,Blasetto JW. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95(3):360-6.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes:the Treating to NewTargets (TNT) study. Diabetes Care 2006;29(6):1220–6.

The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet.2005;366(9500):1849-61.

Samuel A, Kristian B, Filion M, Lawrence J, Ernesto L, Schiffrin MD et al. Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review.Am J Med. 2009;122:962-70.

Hamilton SJ, Chew GT, Davis TM, Watts GF. Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. DiabVasc Dis Res.2010;7:296-9.

Larrey D. Hepatotoxicité des hypolipémiants. GastroenterolHepatol2004;6:407-13.

Danchin N, Chadarevian R, Gayet JL, Licour M, Valensi P. Compared with atorvastatin at the dose of 10mg per day rosuvastatin was more effective to reach an LDL goal of <1.00 g/l in high cardiovascular risk patients (ARIANE study). Ann CardiolAngiol.2007;56(2):82-7.

Mallat A. Hépatites médicamenteuses: diagnostic et prise en charge. Gastroenterol Clin Biol1999;23:906-14. French.

Larrey D. Foie, médicaments et agents chimiques. Gastroenterol Clin Biol.2009;33(12):1136-46. French.

Pichon N, Vincensini JF, Rozière A, Labrousse F, Sautereau D, Pillegand B. Hépatite aiguë cytolytique et cholestatique induite par le fénofibrate.Gastroenterol Clin Biol. 2003; 27(10):947. French.

Hansen KE, Hildebrand JP, Ferguson EE. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671-6.

Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97(8A):52-60.

Wilke RA, Lin DW, Roden DM. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev. 2007;6(11):904-16.

Ginsberg HN, Elam MB, Lovato L. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med.2010;362(17):1563–74.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ.1997;315(7109):629–34.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

How to Cite
Htira, Y., Dridi, M., Hadj Ali, Z., Trabelsi, N., & Ben Mami, F. (2022). Efficacy, Safety and Protective Effects of Lipid Lowering Drugs in Patients with Diabetes. European Journal of Medical and Health Sciences, 4(2), 89–92. https://doi.org/10.24018/ejmed.2022.4.2.1220